ScholarLens Back to search
2016•Value in HealthOpen access

TOCILIZUMAB MONOTHERAPY IN PATIENTS WHERE METHOTREXATE IS CONSIDERED INAPPROPRIATE: A CANADIAN COST-UTILITY ANALYSIS

John-Paul Marino, Alexander Diamantopoulos, M. Duong, J.M. Boam

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Tocilizumab, Adalimumab, Etanercept, Medicine, Rheumatoid arthritis, Methotrexate, Internal medicine, Infliximab

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
TOCILIZUMAB MONOTHERAPY IN PATIENTS WHERE METHOTREXATE IS CONSIDERED INAPPROPRIATE: A CANADIAN COST-UTILITY ANALYSIS — Research Paper | ScholarLens